Based in New Jersey, Becton, Dickinson and Company (BDX – Analyst Report) is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. These products are used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Currently, Becton, Dickinson has a Zacks Rank #2 (Buy) but that could change following its second-quarter fiscal 2015 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate remained steady at $1.54 per share over the last 7 days. Becton, Dickinson’s adjusted earnings of $1.61 per share comfortably beat this estimate. Earnings also increased 1.3% on a year-over-year basis.
Revenues: Revenues amounted to $2.05 billion, down 1% from the prior-year quarter. However, it was marginally higher than the Zacks Consensus Estimate of $2.03 billion.
Key Stats: BD Lifesciences generated revenues of $945 million, down 1.1% from the year-ago quarter. BD Medical generated revenues of $1.10 billion, down 0.9%.
Major Factors: Becton, Dickinson expects adjusted earnings per share for fiscal 2015 to be in the band of $7.00–$7.10. CareFusion is expected to be accretive to adjusted earnings per share in fiscal 2016.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
